4:01 AM
 | 
Jan 04, 2019
 |  BC Extra  |  Financial News

Ribon raises $65 million series B to target monoPARPs

A $65 million series B round will help Ribon Therapeutics Inc. (Lexington, Mass.) move its lead small molecule PARP-7 inhibitor into the clinic this year for squamous cell carcinoma of the lung. New investor Novartis Venture Fund led the round, which was announced Friday.

Novartis Venture's Anja Koenig told BioCentury the fund...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >